{"timeline":{"headline":"Branch Vein Occlusion Study","type":"default","text":"History of NCT00000162","startDate":"2005,06,23","date": [{"startDate":"2005,06,23","headline":"View of NCT00000162 on 2005_06_23","text":"<table class=\"info\">\n<tr>\n<th nowrap=\"\">ClinicalTrials Identifier:</th><td>NCT00000162</td>\n</tr>\n<tr>\n<th>Updated:</th><td>2005_06_23</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Descriptive Information</h2>\n</th>\n</tr>\n<tr>\n<th>Brief title</th><td>\n<p>Branch Vein Occlusion Study</p>\n</td>\n</tr>\n<tr>\n<th>Official title</th><td>\n<p></p>\n</td>\n</tr>\n<tr>\n<th>Brief summary</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>To determine whether scatter argon laser photocoagulation can prevent the development of neovascularization.<br/>\n<br/>\n<br/> \u00a0\u00a0\u00a0\u00a0\u00a0To determine whether peripheral scatter argon laser photocoagulation can prevent vitreous hemorrhage.<br/>\n<br/>\n<br/> \u00a0\u00a0\u00a0\u00a0\u00a0To determine whether macular argon laser photocoagulation can improve visual acuity in eyes with macular edema reducing vision to 20/40 or worse.</p>\n</td>\n</tr>\n<tr>\n<th>Detailed description</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>Retinal branch vein occlusion (BVO) is the second most common retinal vascular disease after diabetic retinopathy. \u00a0Many treatments for this disorder were attempted before 1977, but none were proven to be effective. \u00a0The only treatment that seemed at all promising in preventing visual loss from BVO was laser photocoagulation.<br/>\n<br/>\n<br/> \u00a0\u00a0\u00a0\u00a0\u00a0Approximately 500 patients were enrolled in the study. \u00a0One-half were randomly assigned to treatment with argon laser photocoagulation; the other one-half remained untreated as controls. \u00a0For BVO with or without neovascularization, scatter treatment of 100 to 400 laser burns was applied in the drainage area of the occluded vein site, avoiding the fovea and optic disc. \u00a0Individual laser burns were 200 to 500 microns in diameter with an exposure time of 0.1 to 0.2 seconds. \u00a0For macular edema, burns of 50 to 100 microns in diameter with exposure time of 0.05 to 0.1 seconds were used. \u00a0A fluorescein angiogram less than 1 month old had to have been available for each patient. \u00a0Treatment was performed under topical anesthesia using the argon laser to achieve a grid pattern over the area of capillary leakage identified by fluorescein in the macular region. \u00a0Photocoagulation was extended no closer to the fovea than the edge of the foveal avascular zone and did not extend peripherally beyond the major vascular arcade. \u00a0The efficacy of treatment was judged on the basis of visual acuity measurements as well as assessment of the subsequent development of neovascularization and/or vitreous hemorrhage. \u00a0Patients were followed for at least 3 years.</p>\n</td>\n</tr>\n<tr>\n<th>Phase</th><td>Phase 3</td>\n</tr>\n<tr>\n<th>Study type</th><td>Interventional</td>\n</tr>\n<tr>\n<th>Study design</th><td>Treatment</td>\n</tr>\n<tr>\n<th>Study design</th><td>Randomized</td>\n</tr>\n<tr>\n<th>Condition</th><td>\n         Macular Degeneration\n      </td>\n</tr>\n<tr>\n<th>Condition</th><td>\n         Neovascularization, Pathologic\n      </td>\n</tr>\n<tr>\n<th>Condition</th><td>\n         Vitreous Hemorrhage\n      </td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Procedure: Macular Argon Laser Photocoagulation</div>\n</td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Procedure: Peripheral Scatter Argon Laser Photocoagulation</div>\n</td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Procedure: Scatter Argon Laser Photocoagulation</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Branch Vein Occlusion Study Group; Argon laser photocoagulation for macular edema in branch vein occlusion., Am J Ophthalmol 1984;98:271-282</div>\n<div>MEDLINE: 84304395</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Branch Vein Occlusion Study Group; Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion, Arch Ophthalmol 1986;104</div>\n<div>MEDLINE: 86102749</div>\n</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Recruitment Information</h2>\n</th>\n</tr>\n<tr>\n<th>Status</th><td>\n            Completed\n         </td>\n</tr>\n<tr>\n<th>Start date</th><td>\n         1977-07\n      </td>\n</tr>\n<tr>\n<th>Criteria</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>Patients with three types of diagnoses were accepted:<br/>(1) \u00a0major BVO without neovascularization;<br/>(2) \u00a0major BVO with neovascularization;<br/>(3) \u00a0BVO with macular edema and reduced vision.<br/>All patients must have had onset of signs and/or symptoms of BVO less than 18 months before the initial visit, vision of 5/200 or better, and sufficient clarity of the ocular media to permit confirmation of the condition with fundus photography. \u00a0Other eligibility criteria apply to each of the three major groups as well as special cases such as the occurrence of bilateral disease.</p>\n</td>\n</tr>\n<tr>\n<th>Gender</th><td>\n            Both\n         </td>\n</tr>\n<tr>\n<th>Minimum age</th><td>N/A</td>\n</tr>\n<tr>\n<th>Maximum age</th><td>N/A</td>\n</tr>\n<tr>\n<th>Healthy volunteers</th><td>No</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Administrative Data</h2>\n</th>\n</tr>\n<tr>\n<th>Organization name</th><td>National Eye Institute (NEI)</td>\n</tr>\n<tr>\n<th>Organization study ID</th><td>NEI-64</td>\n</tr>\n<tr>\n<th>Sponsor</th><td>\n               National Eye Institute (NEI)\n            </td>\n</tr>\n<tr>\n<th>Health Authority</th><td>\n               United States: Federal Government\n         </td>\n</tr>\n</table>","asset":{"media":"","credit":"clinicaltrials.gov","caption":""}},{"startDate":"2005,06,30","headline":"View of NCT00000162 on 2005_06_30","text":"<body style=\"display:table; border-collapse:separate; border-spacing:10px;\"><div class=\"separation\" id=\"current\" style=\"display: table-cell; padding: 10px; border: 3px; border-style: solid; border-color: #bbbbbb;\"><table class=\"info\">\n<tr>\n<th nowrap=\"\">ClinicalTrials Identifier:</th><td>NCT00000162</td>\n</tr>\n<tr>\n<th>Updated:</th><td>2005_06_30</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Descriptive Information</h2>\n</th>\n</tr>\n<tr>\n<th>Brief title</th><td>\n<p>Branch Vein Occlusion Study</p>\n</td>\n</tr>\n<tr>\n<th>Official title</th><td>\n<p></p>\n</td>\n</tr>\n<tr>\n<th>Brief summary</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>To determine whether scatter argon laser photocoagulation can prevent the development of neovascularization.<br/>\n<br/>\n<br/> \u00a0\u00a0\u00a0\u00a0\u00a0To determine whether peripheral scatter argon laser photocoagulation can prevent vitreous hemorrhage.<br/>\n<br/>\n<br/> \u00a0\u00a0\u00a0\u00a0\u00a0To determine whether macular argon laser photocoagulation can improve visual acuity in eyes with macular edema reducing vision to 20/40 or worse.</p>\n</td>\n</tr>\n<tr>\n<th>Detailed description</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>Retinal branch vein occlusion (BVO) is the second most common retinal vascular disease after diabetic retinopathy. \u00a0Many treatments for this disorder were attempted before 1977, but none were proven to be effective. \u00a0The only treatment that seemed at all promising in preventing visual loss from BVO was laser photocoagulation.<br/>\n<br/>\n<br/> \u00a0\u00a0\u00a0\u00a0\u00a0Approximately 500 patients were enrolled in the study. \u00a0One-half were randomly assigned to treatment with argon laser photocoagulation; the other one-half remained untreated as controls. \u00a0For BVO with or without neovascularization, scatter treatment of 100 to 400 laser burns was applied in the drainage area of the occluded vein site, avoiding the fovea and optic disc. \u00a0Individual laser burns were 200 to 500 microns in diameter with an exposure time of 0.1 to 0.2 seconds. \u00a0For macular edema, burns of 50 to 100 microns in diameter with exposure time of 0.05 to 0.1 seconds were used. \u00a0A fluorescein angiogram less than 1 month old had to have been available for each patient. \u00a0Treatment was performed under topical anesthesia using the argon laser to achieve a grid pattern over the area of capillary leakage identified by fluorescein in the macular region. \u00a0Photocoagulation was extended no closer to the fovea than the edge of the foveal avascular zone and did not extend peripherally beyond the major vascular arcade. \u00a0The efficacy of treatment was judged on the basis of visual acuity measurements as well as assessment of the subsequent development of neovascularization and/or vitreous hemorrhage. \u00a0Patients were followed for at least 3 years.</p>\n</td>\n</tr>\n<tr>\n<th>Phase</th><td>Phase 3</td>\n</tr>\n<tr>\n<th>Study type</th><td>Interventional</td>\n</tr>\n<tr>\n<th>Study design</th><td>Treatment</td>\n</tr>\n<tr>\n<th>Study design</th><td>Randomized</td>\n</tr>\n<tr>\n<th>Condition</th><td>\n         Macular Degeneration\n      </td>\n</tr>\n<tr>\n<th>Condition</th><td>\n         Neovascularization, Pathologic\n      </td>\n</tr>\n<tr>\n<th>Condition</th><td>\n         Vitreous Hemorrhage\n      </td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Procedure: Macular Argon Laser Photocoagulation</div>\n</td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Procedure: Peripheral Scatter Argon Laser Photocoagulation</div>\n</td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Procedure: Scatter Argon Laser Photocoagulation</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Branch Vein Occlusion Study Group; Argon laser photocoagulation for macular edema in branch vein occlusion., Am J Ophthalmol 1984;98:271-282</div>\n<div>MEDLINE: 84304395</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Branch Vein Occlusion Study Group; Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion, Arch Ophthalmol 1986;104</div>\n<div>MEDLINE: 86102749</div>\n</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Recruitment Information</h2>\n</th>\n</tr>\n<tr>\n<th>Status</th><td>\n            Completed\n         </td>\n</tr>\n<tr>\n<th>Start date</th><td>\n         1977-07\n      </td>\n</tr>\n<tr>\n<th>Criteria</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>Patients with three types of diagnoses were accepted:<br/>(1) \u00a0major BVO without neovascularization;<br/>(2) \u00a0major BVO with neovascularization;<br/>(3) \u00a0BVO with macular edema and reduced vision.<br/>All patients must have had onset of signs and/or symptoms of BVO less than 18 months before the initial visit, vision of 5/200 or better, and sufficient clarity of the ocular media to permit confirmation of the condition with fundus photography. \u00a0Other eligibility criteria apply to each of the three major groups as well as special cases such as the occurrence of bilateral disease.</p>\n</td>\n</tr>\n<tr>\n<th>Gender</th><td>\n            Both\n         </td>\n</tr>\n<tr>\n<th>Minimum age</th><td>N/A</td>\n</tr>\n<tr>\n<th>Maximum age</th><td>N/A</td>\n</tr>\n<tr>\n<th>Healthy volunteers</th><td>No</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Administrative Data</h2>\n</th>\n</tr>\n<tr>\n<th>Organization name</th><td>National Eye Institute (NEI)</td>\n</tr>\n<tr>\n<th>Organization study ID</th><td>NEI-64</td>\n</tr>\n<tr>\n<th>Sponsor</th><td>\n               National Eye Institute (NEI)\n            </td>\n</tr>\n<tr>\n<th>Health Authority</th><td>\n               United States: Federal Government\n         </td>\n</tr>\n</table></div><div class=\"separation\" id=\"past\" style=\"display: table-cell; padding: 10px; border: 3px; border-style: solid; border-color: #bbbbbb;\"><html><body><span>&lt;table class=\"info\"&gt;<br/>&lt;tr&gt;<br/>&lt;th nowrap=\"\"&gt;ClinicalTrials Identifier:&lt;/th&gt;&lt;td&gt;NCT00000162&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Updated:&lt;/th&gt;&lt;td&gt;2005_06_</span><del style=\"background:#ffe6e6;\">2</del><span>3</span><ins style=\"background:#e6ffe6;\">0</ins><span>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th class=\"section\" colspan=\"2\"&gt;<br/>&lt;h2&gt;Descriptive Information&lt;/h2&gt;<br/>&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Brief title&lt;/th&gt;&lt;td&gt;<br/>&lt;p&gt;Branch Vein Occlusion Study&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Official title&lt;/th&gt;&lt;td&gt;<br/>&lt;p&gt;&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Brief summary&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;td class=\"bigdent\" colspan=\"2\"&gt;<br/>&lt;p&gt;To determine whether scatter argon laser photocoagulation can prevent the development of neovascularization.&lt;br/&gt;<br/>&lt;br/&gt;<br/>&lt;br/&gt; \u00a0\u00a0\u00a0\u00a0\u00a0To determine whether peripheral scatter argon laser photocoagulation can prevent vitreous hemorrhage.&lt;br/&gt;<br/>&lt;br/&gt;<br/>&lt;br/&gt; \u00a0\u00a0\u00a0\u00a0\u00a0To determine whether macular argon laser photocoagulation can improve visual acuity in eyes with macular edema reducing vision to 20/40 or worse.&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Detailed description&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;td class=\"bigdent\" colspan=\"2\"&gt;<br/>&lt;p&gt;Retinal branch vein occlusion (BVO) is the second most common retinal vascular disease after diabetic retinopathy. \u00a0Many treatments for this disorder were attempted before 1977, but none were proven to be effective. \u00a0The only treatment that seemed at all promising in preventing visual loss from BVO was laser photocoagulation.&lt;br/&gt;<br/>&lt;br/&gt;<br/>&lt;br/&gt; \u00a0\u00a0\u00a0\u00a0\u00a0Approximately 500 patients were enrolled in the study. \u00a0One-half were randomly assigned to treatment with argon laser photocoagulation; the other one-half remained untreated as controls. \u00a0For BVO with or without neovascularization, scatter treatment of 100 to 400 laser burns was applied in the drainage area of the occluded vein site, avoiding the fovea and optic disc. \u00a0Individual laser burns were 200 to 500 microns in diameter with an exposure time of 0.1 to 0.2 seconds. \u00a0For macular edema, burns of 50 to 100 microns in diameter with exposure time of 0.05 to 0.1 seconds were used. \u00a0A fluorescein angiogram less than 1 month old had to have been available for each patient. \u00a0Treatment was performed under topical anesthesia using the argon laser to achieve a grid pattern over the area of capillary leakage identified by fluorescein in the macular region. \u00a0Photocoagulation was extended no closer to the fovea than the edge of the foveal avascular zone and did not extend peripherally beyond the major vascular arcade. \u00a0The efficacy of treatment was judged on the basis of visual acuity measurements as well as assessment of the subsequent development of neovascularization and/or vitreous hemorrhage. \u00a0Patients were followed for at least 3 years.&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Phase&lt;/th&gt;&lt;td&gt;Phase 3&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Study type&lt;/th&gt;&lt;td&gt;Interventional&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Study design&lt;/th&gt;&lt;td&gt;Treatment&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Study design&lt;/th&gt;&lt;td&gt;Randomized&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Condition&lt;/th&gt;&lt;td&gt;<br/>         Macular Degeneration<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Condition&lt;/th&gt;&lt;td&gt;<br/>         Neovascularization, Pathologic<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Condition&lt;/th&gt;&lt;td&gt;<br/>         Vitreous Hemorrhage<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Intervention&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Procedure: Macular Argon Laser Photocoagulation&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Intervention&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Procedure: Peripheral Scatter Argon Laser Photocoagulation&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Intervention&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Procedure: Scatter Argon Laser Photocoagulation&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: Branch Vein Occlusion Study Group; Argon laser photocoagulation for macular edema in branch vein occlusion., Am J Ophthalmol 1984;98:271-282&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 84304395&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: Branch Vein Occlusion Study Group; Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion, Arch Ophthalmol 1986;104&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 86102749&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th class=\"section\" colspan=\"2\"&gt;<br/>&lt;h2&gt;Recruitment Information&lt;/h2&gt;<br/>&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Status&lt;/th&gt;&lt;td&gt;<br/>            Completed<br/>         &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Start date&lt;/th&gt;&lt;td&gt;<br/>         1977-07<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Criteria&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;td class=\"bigdent\" colspan=\"2\"&gt;<br/>&lt;p&gt;Patients with three types of diagnoses were accepted:&lt;br/&gt;(1) \u00a0major BVO without neovascularization;&lt;br/&gt;(2) \u00a0major BVO with neovascularization;&lt;br/&gt;(3) \u00a0BVO with macular edema and reduced vision.&lt;br/&gt;All patients must have had onset of signs and/or symptoms of BVO less than 18 months before the initial visit, vision of 5/200 or better, and sufficient clarity of the ocular media to permit confirmation of the condition with fundus photography. \u00a0Other eligibility criteria apply to each of the three major groups as well as special cases such as the occurrence of bilateral disease.&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Gender&lt;/th&gt;&lt;td&gt;<br/>            Both<br/>         &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Minimum age&lt;/th&gt;&lt;td&gt;N/A&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Maximum age&lt;/th&gt;&lt;td&gt;N/A&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Healthy volunteers&lt;/th&gt;&lt;td&gt;No&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th class=\"section\" colspan=\"2\"&gt;<br/>&lt;h2&gt;Administrative Data&lt;/h2&gt;<br/>&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Organization name&lt;/th&gt;&lt;td&gt;National Eye Institute (NEI)&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Organization study ID&lt;/th&gt;&lt;td&gt;NEI-64&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Sponsor&lt;/th&gt;&lt;td&gt;<br/>               National Eye Institute (NEI)<br/>            &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Health Authority&lt;/th&gt;&lt;td&gt;<br/>               United States: Federal Government<br/>         &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;/table&gt;</span></body></html></div></body>","asset":{"media":"","credit":"clinicaltrials.gov","caption":""}},{"startDate":"2005,12,08","headline":"View of NCT00000162 on 2005_12_08","text":"<body style=\"display:table; border-collapse:separate; border-spacing:10px;\"><div class=\"separation\" id=\"current\" style=\"display: table-cell; padding: 10px; border: 3px; border-style: solid; border-color: #bbbbbb;\"><table class=\"info\">\n<tr>\n<th nowrap=\"\">ClinicalTrials Identifier:</th><td>NCT00000162</td>\n</tr>\n<tr>\n<th>Updated:</th><td>2005_12_08</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Descriptive Information</h2>\n</th>\n</tr>\n<tr>\n<th>Brief title</th><td>\n<p>Branch Vein Occlusion Study</p>\n</td>\n</tr>\n<tr>\n<th>Official title</th><td>\n<p></p>\n</td>\n</tr>\n<tr>\n<th>Brief summary</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>To determine whether scatter argon laser photocoagulation can prevent the development of neovascularization.<br/>\n<br/>\n<br/> \u00a0\u00a0\u00a0\u00a0\u00a0To determine whether peripheral scatter argon laser photocoagulation can prevent vitreous hemorrhage.<br/>\n<br/>\n<br/> \u00a0\u00a0\u00a0\u00a0\u00a0To determine whether macular argon laser photocoagulation can improve visual acuity in eyes with macular edema reducing vision to 20/40 or worse.</p>\n</td>\n</tr>\n<tr>\n<th>Detailed description</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>Retinal branch vein occlusion (BVO) is the second most common retinal vascular disease after diabetic retinopathy. \u00a0Many treatments for this disorder were attempted before 1977, but none were proven to be effective. \u00a0The only treatment that seemed at all promising in preventing visual loss from BVO was laser photocoagulation.<br/>\n<br/>\n<br/> \u00a0\u00a0\u00a0\u00a0\u00a0Approximately 500 patients were enrolled in the study. \u00a0One-half were randomly assigned to treatment with argon laser photocoagulation; the other one-half remained untreated as controls. \u00a0For BVO with or without neovascularization, scatter treatment of 100 to 400 laser burns was applied in the drainage area of the occluded vein site, avoiding the fovea and optic disc. \u00a0Individual laser burns were 200 to 500 microns in diameter with an exposure time of 0.1 to 0.2 seconds. \u00a0For macular edema, burns of 50 to 100 microns in diameter with exposure time of 0.05 to 0.1 seconds were used. \u00a0A fluorescein angiogram less than 1 month old had to have been available for each patient. \u00a0Treatment was performed under topical anesthesia using the argon laser to achieve a grid pattern over the area of capillary leakage identified by fluorescein in the macular region. \u00a0Photocoagulation was extended no closer to the fovea than the edge of the foveal avascular zone and did not extend peripherally beyond the major vascular arcade. \u00a0The efficacy of treatment was judged on the basis of visual acuity measurements as well as assessment of the subsequent development of neovascularization and/or vitreous hemorrhage. \u00a0Patients were followed for at least 3 years.</p>\n</td>\n</tr>\n<tr>\n<th>Phase</th><td>Phase 3</td>\n</tr>\n<tr>\n<th>Study type</th><td>Interventional</td>\n</tr>\n<tr>\n<th>Study design</th><td>Treatment</td>\n</tr>\n<tr>\n<th>Study design</th><td>Randomized</td>\n</tr>\n<tr>\n<th>Condition</th><td>\n         Macular Degeneration\n      </td>\n</tr>\n<tr>\n<th>Condition</th><td>\n         Neovascularization, Pathologic\n      </td>\n</tr>\n<tr>\n<th>Condition</th><td>\n         Vitreous Hemorrhage\n      </td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Procedure: Macular Argon Laser Photocoagulation</div>\n</td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Procedure: Peripheral Scatter Argon Laser Photocoagulation</div>\n</td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Procedure: Scatter Argon Laser Photocoagulation</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Branch Vein Occlusion Study Group; Argon laser photocoagulation for macular edema in branch vein occlusion., Am J Ophthalmol 1984;98:271-282</div>\n<div>MEDLINE: 84304395</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Branch Vein Occlusion Study Group; Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion, Arch Ophthalmol 1986;104</div>\n<div>MEDLINE: 86102749</div>\n</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Recruitment Information</h2>\n</th>\n</tr>\n<tr>\n<th>Status</th><td>\n            Completed\n         </td>\n</tr>\n<tr>\n<th>Start date</th><td>\n         1977-07\n      </td>\n</tr>\n<tr>\n<th>Criteria</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>Patients with three types of diagnoses were accepted:<br/>(1) \u00a0major BVO without neovascularization;<br/>(2) \u00a0major BVO with neovascularization;<br/>(3) \u00a0BVO with macular edema and reduced vision.<br/>All patients must have had onset of signs and/or symptoms of BVO less than 18 months before the initial visit, vision of 5/200 or better, and sufficient clarity of the ocular media to permit confirmation of the condition with fundus photography. \u00a0Other eligibility criteria apply to each of the three major groups as well as special cases such as the occurrence of bilateral disease.</p>\n</td>\n</tr>\n<tr>\n<th>Gender</th><td>\n            Both\n         </td>\n</tr>\n<tr>\n<th>Minimum age</th><td>N/A</td>\n</tr>\n<tr>\n<th>Maximum age</th><td>N/A</td>\n</tr>\n<tr>\n<th>Healthy volunteers</th><td>No</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Administrative Data</h2>\n</th>\n</tr>\n<tr>\n<th>Organization name</th><td>National Eye Institute (NEI)</td>\n</tr>\n<tr>\n<th>Organization study ID</th><td>NEI-64</td>\n</tr>\n<tr>\n<th>Sponsor</th><td>\n               National Eye Institute (NEI)\n            </td>\n</tr>\n<tr>\n<th>Health Authority</th><td>\n               United States: Federal Government\n         </td>\n</tr>\n</table></div><div class=\"separation\" id=\"past\" style=\"display: table-cell; padding: 10px; border: 3px; border-style: solid; border-color: #bbbbbb;\"><html><body><span>&lt;table class=\"info\"&gt;<br/>&lt;tr&gt;<br/>&lt;th nowrap=\"\"&gt;ClinicalTrials Identifier:&lt;/th&gt;&lt;td&gt;NCT00000162&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Updated:&lt;/th&gt;&lt;td&gt;2005_</span><del style=\"background:#ffe6e6;\">06_30</del><ins style=\"background:#e6ffe6;\">12_08</ins><span>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th class=\"section\" colspan=\"2\"&gt;<br/>&lt;h2&gt;Descriptive Information&lt;/h2&gt;<br/>&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Brief title&lt;/th&gt;&lt;td&gt;<br/>&lt;p&gt;Branch Vein Occlusion Study&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Official title&lt;/th&gt;&lt;td&gt;<br/>&lt;p&gt;&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Brief summary&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;td class=\"bigdent\" colspan=\"2\"&gt;<br/>&lt;p&gt;To determine whether scatter argon laser photocoagulation can prevent the development of neovascularization.&lt;br/&gt;<br/>&lt;br/&gt;<br/>&lt;br/&gt; \u00a0\u00a0\u00a0\u00a0\u00a0To determine whether peripheral scatter argon laser photocoagulation can prevent vitreous hemorrhage.&lt;br/&gt;<br/>&lt;br/&gt;<br/>&lt;br/&gt; \u00a0\u00a0\u00a0\u00a0\u00a0To determine whether macular argon laser photocoagulation can improve visual acuity in eyes with macular edema reducing vision to 20/40 or worse.&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Detailed description&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;td class=\"bigdent\" colspan=\"2\"&gt;<br/>&lt;p&gt;Retinal branch vein occlusion (BVO) is the second most common retinal vascular disease after diabetic retinopathy. \u00a0Many treatments for this disorder were attempted before 1977, but none were proven to be effective. \u00a0The only treatment that seemed at all promising in preventing visual loss from BVO was laser photocoagulation.&lt;br/&gt;<br/>&lt;br/&gt;<br/>&lt;br/&gt; \u00a0\u00a0\u00a0\u00a0\u00a0Approximately 500 patients were enrolled in the study. \u00a0One-half were randomly assigned to treatment with argon laser photocoagulation; the other one-half remained untreated as controls. \u00a0For BVO with or without neovascularization, scatter treatment of 100 to 400 laser burns was applied in the drainage area of the occluded vein site, avoiding the fovea and optic disc. \u00a0Individual laser burns were 200 to 500 microns in diameter with an exposure time of 0.1 to 0.2 seconds. \u00a0For macular edema, burns of 50 to 100 microns in diameter with exposure time of 0.05 to 0.1 seconds were used. \u00a0A fluorescein angiogram less than 1 month old had to have been available for each patient. \u00a0Treatment was performed under topical anesthesia using the argon laser to achieve a grid pattern over the area of capillary leakage identified by fluorescein in the macular region. \u00a0Photocoagulation was extended no closer to the fovea than the edge of the foveal avascular zone and did not extend peripherally beyond the major vascular arcade. \u00a0The efficacy of treatment was judged on the basis of visual acuity measurements as well as assessment of the subsequent development of neovascularization and/or vitreous hemorrhage. \u00a0Patients were followed for at least 3 years.&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Phase&lt;/th&gt;&lt;td&gt;Phase 3&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Study type&lt;/th&gt;&lt;td&gt;Interventional&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Study design&lt;/th&gt;&lt;td&gt;Treatment&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Study design&lt;/th&gt;&lt;td&gt;Randomized&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Condition&lt;/th&gt;&lt;td&gt;<br/>         Macular Degeneration<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Condition&lt;/th&gt;&lt;td&gt;<br/>         Neovascularization, Pathologic<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Condition&lt;/th&gt;&lt;td&gt;<br/>         Vitreous Hemorrhage<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Intervention&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Procedure: Macular Argon Laser Photocoagulation&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Intervention&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Procedure: Peripheral Scatter Argon Laser Photocoagulation&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Intervention&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Procedure: Scatter Argon Laser Photocoagulation&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: Branch Vein Occlusion Study Group; Argon laser photocoagulation for macular edema in branch vein occlusion., Am J Ophthalmol 1984;98:271-282&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 84304395&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: Branch Vein Occlusion Study Group; Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion, Arch Ophthalmol 1986;104&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: 86102749&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th class=\"section\" colspan=\"2\"&gt;<br/>&lt;h2&gt;Recruitment Information&lt;/h2&gt;<br/>&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Status&lt;/th&gt;&lt;td&gt;<br/>            Completed<br/>         &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Start date&lt;/th&gt;&lt;td&gt;<br/>         1977-07<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Criteria&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;td class=\"bigdent\" colspan=\"2\"&gt;<br/>&lt;p&gt;Patients with three types of diagnoses were accepted:&lt;br/&gt;(1) \u00a0major BVO without neovascularization;&lt;br/&gt;(2) \u00a0major BVO with neovascularization;&lt;br/&gt;(3) \u00a0BVO with macular edema and reduced vision.&lt;br/&gt;All patients must have had onset of signs and/or symptoms of BVO less than 18 months before the initial visit, vision of 5/200 or better, and sufficient clarity of the ocular media to permit confirmation of the condition with fundus photography. \u00a0Other eligibility criteria apply to each of the three major groups as well as special cases such as the occurrence of bilateral disease.&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Gender&lt;/th&gt;&lt;td&gt;<br/>            Both<br/>         &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Minimum age&lt;/th&gt;&lt;td&gt;N/A&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Maximum age&lt;/th&gt;&lt;td&gt;N/A&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Healthy volunteers&lt;/th&gt;&lt;td&gt;No&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th class=\"section\" colspan=\"2\"&gt;<br/>&lt;h2&gt;Administrative Data&lt;/h2&gt;<br/>&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Organization name&lt;/th&gt;&lt;td&gt;National Eye Institute (NEI)&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Organization study ID&lt;/th&gt;&lt;td&gt;NEI-64&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Sponsor&lt;/th&gt;&lt;td&gt;<br/>               National Eye Institute (NEI)<br/>            &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Health Authority&lt;/th&gt;&lt;td&gt;<br/>               United States: Federal Government<br/>         &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;/table&gt;</span></body></html></div></body>","asset":{"media":"","credit":"clinicaltrials.gov","caption":""}},{"startDate":"2014,03,14","headline":"View of NCT00000162 on 2014_03_14","text":"<body style=\"display:table; border-collapse:separate; border-spacing:10px;\"><div class=\"separation\" id=\"current\" style=\"display: table-cell; padding: 10px; border: 3px; border-style: solid; border-color: #bbbbbb;\"><table class=\"info\">\n<tr>\n<th nowrap=\"\">ClinicalTrials Identifier:</th><td>NCT00000162</td>\n</tr>\n<tr>\n<th>Updated:</th><td>2014_03_14</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Descriptive Information</h2>\n</th>\n</tr>\n<tr>\n<th>Brief title</th><td>\n<p>Branch Vein Occlusion Study</p>\n</td>\n</tr>\n<tr>\n<th>Official title</th><td>\n<p></p>\n</td>\n</tr>\n<tr>\n<th>Brief summary</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>To determine whether scatter argon laser photocoagulation can prevent the development of neovascularization.<br/>\n<br/>\n<br/> \u00a0\u00a0\u00a0\u00a0\u00a0To determine whether peripheral scatter argon laser photocoagulation can prevent vitreous hemorrhage.<br/>\n<br/>\n<br/> \u00a0\u00a0\u00a0\u00a0\u00a0To determine whether macular argon laser photocoagulation can improve visual acuity in eyes with macular edema reducing vision to 20/40 or worse.</p>\n</td>\n</tr>\n<tr>\n<th>Detailed description</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>Retinal branch vein occlusion (BVO) is the second most common retinal vascular disease after diabetic retinopathy. \u00a0Many treatments for this disorder were attempted before 1977, but none were proven to be effective. \u00a0The only treatment that seemed at all promising in preventing visual loss from BVO was laser photocoagulation.<br/>\n<br/>\n<br/> \u00a0\u00a0\u00a0\u00a0\u00a0Approximately 500 patients were enrolled in the study. \u00a0One-half were randomly assigned to treatment with argon laser photocoagulation; the other one-half remained untreated as controls. \u00a0For BVO with or without neovascularization, scatter treatment of 100 to 400 laser burns was applied in the drainage area of the occluded vein site, avoiding the fovea and optic disc. \u00a0Individual laser burns were 200 to 500 microns in diameter with an exposure time of 0.1 to 0.2 seconds. \u00a0For macular edema, burns of 50 to 100 microns in diameter with exposure time of 0.05 to 0.1 seconds were used. \u00a0A fluorescein angiogram less than 1 month old had to have been available for each patient. \u00a0Treatment was performed under topical anesthesia using the argon laser to achieve a grid pattern over the area of capillary leakage identified by fluorescein in the macular region. \u00a0Photocoagulation was extended no closer to the fovea than the edge of the foveal avascular zone and did not extend peripherally beyond the major vascular arcade. \u00a0The efficacy of treatment was judged on the basis of visual acuity measurements as well as assessment of the subsequent development of neovascularization and/or vitreous hemorrhage. \u00a0Patients were followed for at least 3 years.</p>\n</td>\n</tr>\n<tr>\n<th>Phase</th><td>Phase 3</td>\n</tr>\n<tr>\n<th>Study type</th><td>Interventional</td>\n</tr>\n<tr>\n<th>Study design</th><td>Treatment</td>\n</tr>\n<tr>\n<th>Study design</th><td>Randomized</td>\n</tr>\n<tr>\n<th>Condition</th><td>\n         Macular Degeneration\n      </td>\n</tr>\n<tr>\n<th>Condition</th><td>\n         Neovascularization, Pathologic\n      </td>\n</tr>\n<tr>\n<th>Condition</th><td>\n         Vitreous Hemorrhage\n      </td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Procedure/Surgery: Macular Argon Laser Photocoagulation</div>\n<p></p>\n</td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Procedure/Surgery: Peripheral Scatter Argon Laser Photocoagulation</div>\n<p></p>\n</td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Procedure/Surgery: Scatter Argon Laser Photocoagulation</div>\n<p></p>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Branch Vein Occlusion Study Group; Argon laser photocoagulation for macular edema in branch vein occlusion., Am J Ophthalmol 1984;98:271-282</div>\n<div>MEDLINE: 6383055</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Branch Vein Occlusion Study Group; Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion, Arch Ophthalmol 1986;104</div>\n<div>MEDLINE: 2417579</div>\n</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Recruitment Information</h2>\n</th>\n</tr>\n<tr>\n<th>Status</th><td>Completed</td>\n</tr>\n<tr>\n<th>Start date</th><td>\n         1977-07\n      </td>\n</tr>\n<tr>\n<th>Criteria</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>Patients with three types of diagnoses were accepted:<br/>(1) \u00a0major BVO without neovascularization;<br/>(2) \u00a0major BVO with neovascularization;<br/>(3) \u00a0BVO with macular edema and reduced vision.<br/>All patients must have had onset of signs and/or symptoms of BVO less than 18 months before the initial visit, vision of 5/200 or better, and sufficient clarity of the ocular media to permit confirmation of the condition with fundus photography. \u00a0Other eligibility criteria apply to each of the three major groups as well as special cases such as the occurrence of bilateral disease.</p>\n</td>\n</tr>\n<tr>\n<th>Gender</th><td>\n            Both\n         </td>\n</tr>\n<tr>\n<th>Healthy volunteers</th><td>No</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Administrative Data</h2>\n</th>\n</tr>\n<tr>\n<th>Organization name</th><td>National Eye Institute (NEI)</td>\n</tr>\n<tr>\n<th>Organization study ID</th><td>NEI-64</td>\n</tr>\n<tr>\n<th>Sponsor</th><td>\n               National Eye Institute (NEI)\n            </td>\n</tr>\n<tr>\n<th>Health Authority</th><td>\n               United States: Federal Government\n         </td>\n</tr>\n</table></div><div class=\"separation\" id=\"past\" style=\"display: table-cell; padding: 10px; border: 3px; border-style: solid; border-color: #bbbbbb;\"><html><body><span>&lt;table class=\"info\"&gt;<br/>&lt;tr&gt;<br/>&lt;th nowrap=\"\"&gt;ClinicalTrials Identifier:&lt;/th&gt;&lt;td&gt;NCT00000162&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Updated:&lt;/th&gt;&lt;td&gt;20</span><del style=\"background:#ffe6e6;\">05_12_08</del><ins style=\"background:#e6ffe6;\">14_03_14</ins><span>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th class=\"section\" colspan=\"2\"&gt;<br/>&lt;h2&gt;Descriptive Information&lt;/h2&gt;<br/>&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Brief title&lt;/th&gt;&lt;td&gt;<br/>&lt;p&gt;Branch Vein Occlusion Study&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Official title&lt;/th&gt;&lt;td&gt;<br/>&lt;p&gt;&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Brief summary&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;td class=\"bigdent\" colspan=\"2\"&gt;<br/>&lt;p&gt;To determine whether scatter argon laser photocoagulation can prevent the development of neovascularization.&lt;br/&gt;<br/>&lt;br/&gt;<br/>&lt;br/&gt; \u00a0\u00a0\u00a0\u00a0\u00a0To determine whether peripheral scatter argon laser photocoagulation can prevent vitreous hemorrhage.&lt;br/&gt;<br/>&lt;br/&gt;<br/>&lt;br/&gt; \u00a0\u00a0\u00a0\u00a0\u00a0To determine whether macular argon laser photocoagulation can improve visual acuity in eyes with macular edema reducing vision to 20/40 or worse.&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Detailed description&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;td class=\"bigdent\" colspan=\"2\"&gt;<br/>&lt;p&gt;Retinal branch vein occlusion (BVO) is the second most common retinal vascular disease after diabetic retinopathy. \u00a0Many treatments for this disorder were attempted before 1977, but none were proven to be effective. \u00a0The only treatment that seemed at all promising in preventing visual loss from BVO was laser photocoagulation.&lt;br/&gt;<br/>&lt;br/&gt;<br/>&lt;br/&gt; \u00a0\u00a0\u00a0\u00a0\u00a0Approximately 500 patients were enrolled in the study. \u00a0One-half were randomly assigned to treatment with argon laser photocoagulation; the other one-half remained untreated as controls. \u00a0For BVO with or without neovascularization, scatter treatment of 100 to 400 laser burns was applied in the drainage area of the occluded vein site, avoiding the fovea and optic disc. \u00a0Individual laser burns were 200 to 500 microns in diameter with an exposure time of 0.1 to 0.2 seconds. \u00a0For macular edema, burns of 50 to 100 microns in diameter with exposure time of 0.05 to 0.1 seconds were used. \u00a0A fluorescein angiogram less than 1 month old had to have been available for each patient. \u00a0Treatment was performed under topical anesthesia using the argon laser to achieve a grid pattern over the area of capillary leakage identified by fluorescein in the macular region. \u00a0Photocoagulation was extended no closer to the fovea than the edge of the foveal avascular zone and did not extend peripherally beyond the major vascular arcade. \u00a0The efficacy of treatment was judged on the basis of visual acuity measurements as well as assessment of the subsequent development of neovascularization and/or vitreous hemorrhage. \u00a0Patients were followed for at least 3 years.&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Phase&lt;/th&gt;&lt;td&gt;Phase 3&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Study type&lt;/th&gt;&lt;td&gt;Interventional&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Study design&lt;/th&gt;&lt;td&gt;Treatment&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Study design&lt;/th&gt;&lt;td&gt;Randomized&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Condition&lt;/th&gt;&lt;td&gt;<br/>         Macular Degeneration<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Condition&lt;/th&gt;&lt;td&gt;<br/>         Neovascularization, Pathologic<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Condition&lt;/th&gt;&lt;td&gt;<br/>         Vitreous Hemorrhage<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Intervention&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Procedure</span><ins style=\"background:#e6ffe6;\">/Surgery</ins><span>: Macular Argon Laser Photocoagulation&lt;/div&gt;<br/></span><ins style=\"background:#e6ffe6;\">&lt;p&gt;&lt;/p&gt;<br/></ins><span>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Intervention&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Procedure</span><ins style=\"background:#e6ffe6;\">/Surgery</ins><span>: Peripheral Scatter Argon Laser Photocoagulation&lt;/div&gt;<br/></span><ins style=\"background:#e6ffe6;\">&lt;p&gt;&lt;/p&gt;<br/></ins><span>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Intervention&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Procedure</span><ins style=\"background:#e6ffe6;\">/Surgery</ins><span>: Scatter Argon Laser Photocoagulation&lt;/div&gt;<br/></span><ins style=\"background:#e6ffe6;\">&lt;p&gt;&lt;/p&gt;<br/></ins><span>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: Branch Vein Occlusion Study Group; Argon laser photocoagulation for macular edema in branch vein occlusion., Am J Ophthalmol 1984;98:271-282&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: </span><del style=\"background:#ffe6e6;\">8430439</del><ins style=\"background:#e6ffe6;\">638305</ins><span>5&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: Branch Vein Occlusion Study Group; Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion, Arch Ophthalmol 1986;104&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: </span><del style=\"background:#ffe6e6;\">8610274</del><ins style=\"background:#e6ffe6;\">241757</ins><span>9&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th class=\"section\" colspan=\"2\"&gt;<br/>&lt;h2&gt;Recruitment Information&lt;/h2&gt;<br/>&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Status&lt;/th&gt;&lt;td&gt;</span><del style=\"background:#ffe6e6;\"><br/>            Completed<br/> </del><ins style=\"background:#e6ffe6;\">Completed</ins><span>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Start date&lt;/th&gt;&lt;td&gt;<br/>         1977-07<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Criteria&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;td class=\"bigdent\" colspan=\"2\"&gt;<br/>&lt;p&gt;Patients with three types of diagnoses were accepted:&lt;br/&gt;(1) \u00a0major BVO without neovascularization;&lt;br/&gt;(2) \u00a0major BVO with neovascularization;&lt;br/&gt;(3) \u00a0BVO with macular edema and reduced vision.&lt;br/&gt;All patients must have had onset of signs and/or symptoms of BVO less than 18 months before the initial visit, vision of 5/200 or better, and sufficient clarity of the ocular media to permit confirmation of the condition with fundus photography. \u00a0Other eligibility criteria apply to each of the three major groups as well as special cases such as the occurrence of bilateral disease.&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Gender&lt;/th&gt;&lt;td&gt;<br/>            Both<br/> </span><del style=\"background:#ffe6e6;\">&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Minimum age&lt;/th&gt;&lt;td&gt;N/A&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Maximum age&lt;/th&gt;&lt;td&gt;N/A</del><span></span><ins style=\"background:#e6ffe6;\"></ins><span>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Healthy volunteers&lt;/th&gt;&lt;td&gt;No&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th class=\"section\" colspan=\"2\"&gt;<br/>&lt;h2&gt;Administrative Data&lt;/h2&gt;<br/>&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Organization name&lt;/th&gt;&lt;td&gt;National Eye Institute (NEI)&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Organization study ID&lt;/th&gt;&lt;td&gt;NEI-64&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Sponsor&lt;/th&gt;&lt;td&gt;<br/>               National Eye Institute (NEI)<br/>            &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Health Authority&lt;/th&gt;&lt;td&gt;<br/>               United States: Federal Government<br/>         &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;/table&gt;</span></body></html></div></body>","asset":{"media":"","credit":"clinicaltrials.gov","caption":""}}]}}